Fulgent Genetics, Inc. (FLGT) Cash Flow Statement
Where FLGT’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$101.6M −582.6% vs 2024
- Capital expenditures
- $22.6M 7.0% of revenue
- Free cash flow
- −$124.2M −38.5% margin
- Returned to shareholders
- $13.9M
- Change in cash
- −$5.0M cash at year-end $50.3M
Drawn to scale: where the cash came from and how it was used. Hover for values.
FLGT operating cash flow, capex and free cash flow
FLGT cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $4.4M2016 | −$101.6M2025 | — | |
| Capital expenditures | $3.8M2016 | $22.6M2025 | +21.9%/yr | |
| Free cash flow | $617,0002016 | −$124.2M2025 | — | |
| Free cash flow margin | 3.4%2016 | −38.5%2025 | −41.9 pts | |
| Operating cash flow / net income | 0.662020 | 1.792022 | +1.13 | |
| Stock-based compensation | $4.7M2016 | $39.6M2025 | +26.9%/yr | |
| Dividends paid | $4.6M2016 | $4.2M2021 | −2.0%/yr | |
| Share buybacks (net) | $6.6M2016 | $13.9M2025 | +8.7%/yr | |
| Capex / revenue | 20.7%2016 | 7.0%2025 | −13.7 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
FLGT cash flow by activity
FLGT net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
FLGT cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$61.6M | −$43.8M | −$175.2M | $141.9M | $506.2M | $214.3M | −$411,000 | −$5.6M | −$2.5M | −$5.4M |
| Depreciation & amortization | $24.1M | $24.9M | $26.1M | $32.7M | $11.0M | $3.0M | $2.1M | $2.2M | $1.7M | $1.2M |
| Stock-based compensation | $39.6M | $44.5M | $42.9M | $32.6M | $15.9M | $8.2M | $3.2M | $2.3M | $2.1M | $4.7M |
| Change in working capital | −$117.6M | −$7.2M | $2.8M | $2.0M | −$2.7M | −$91.5M | −$915,000 | −$1.2M | −$714,000 | −$1.9M |
| Other non-cash items | $13.9M | $2.7M | $130.3M | $44.3M | $8.1M | $6.7M | $1.5M | $1.7M | $708,000 | $5.8M |
| Cash from operating activities | −$101.6M | $21.1M | $27.0M | $253.5M | $538.6M | $140.6M | $5.5M | −$675,000 | $1.3M | $4.4M |
| Investing activities | ||||||||||
| Capital expenditures | −$22.6M | −$40.3M | −$22.2M | −$18.8M | −$23.8M | −$36.5M | −$1.2M | −$2.8M | −$5.4M | −$3.8M |
| Investments (net) | $130.2M | −$58.4M | $38.9M | −$261.3M | −$460.9M | −$289.9M | −$27.9M | $3.3M | $3.3M | −$42.8M |
| Acquisitions & other investing | $3.8M | $40.3M | $22.2M | $18.8M | −$61.8M | $8,000 | $0 | $510,000 | $0 | $3.8M |
| Cash from investing activities | $111.4M | −$58.4M | $38.9M | −$261.3M | −$546.5M | −$326.4M | −$29.0M | $950,000 | −$2.0M | −$42.8M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | −$4.2M | −$15.0M | — | — | $0 | −$4.6M |
| Share repurchases & issuance (net) | −$13.9M | −$3.1M | −$27.8M | −$76.1M | −$4.2M | −$62,000 | −$21,000 | $15,000 | $31,000 | −$6.6M |
| Net borrowing (repayment) | −$870,000 | −$1.8M | −$20.0M | −$1.1M | −$11,000 | $15.0M | $15.0M | $15.0M | $15.0M | — |
| Shares issued | $0 | $0 | $0 | $13.8M | $89.5M | $246.2M | $28.8M | $0 | $0 | $0 |
| Other financing | $1,000 | $51,000 | $3,000 | −$13.8M | $4.3M | $15.1M | −$15.0M | −$15.0M | −$15.8M | $57.0M |
| Cash from financing activities | −$14.8M | −$4.8M | −$47.8M | −$77.1M | $85.4M | $261.3M | $28.8M | $15,000 | −$770,000 | $45.8M |
| Summary | ||||||||||
| Net change in cash | −$5.0M | −$42.2M | $18.0M | −$85.4M | $77.5M | $75.5M | $5.2M | $246,000 | −$1.4M | $7.4M |
| Cash at end of period | $50.3M | $55.3M | $97.5M | $79.5M | $164.9M | $87.4M | $12.0M | $6.7M | $6.5M | $7.9M |
| Free cash flow | −$124.2M | −$19.3M | $4.8M | $234.7M | $514.7M | $104.1M | $4.3M | −$3.5M | −$4.0M | $617,000 |
| Free cash flow margin | −38.5% | −6.8% | 1.7% | 37.9% | 51.9% | 24.7% | 13.3% | −16.4% | −21.5% | 3.4% |
| Capex / revenue | 7.0% | 14.2% | 7.7% | 3.0% | 2.4% | 8.7% | 3.6% | 13.3% | 28.6% | 20.7% |
| Operating cash flow / net income | — | — | — | 1.79 | 1.06 | 0.66 | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$30.2M | −$24.8M | −$23.6M | −$6.8M | −$19.3M | −$11.9M | −$6.2M | −$14.7M | −$9.1M | −$13.8M | −$134.3M | −$13.5M |
| Depreciation & amortization | $7.7M | $6.0M | $6.1M | $6.0M | $6.1M | $5.9M | $6.2M | $5.9M | $6.2M | $6.7M | $6.5M | $6.4M |
| Stock-based compensation | $18.5M | $9.9M | $9.3M | $9.7M | $10.0M | $10.6M | $10.4M | $10.9M | $11.6M | $11.5M | $11.4M | $10.9M |
| Change in working capital | −$15.6M | $16.8M | −$71.7M | $2.4M | −$38.5M | −$9.8M | $16.2M | −$25.8M | −$2.6M | $4.9M | $10.2M | −$11.2M |
| Other non-cash items | −$4.1M | −$726,000 | $1.8M | −$206,000 | $11.5M | $790,000 | −$1.6M | $8.1M | −$1.8M | −$2.0M | $121.1M | $17.6M |
| Cash from operating activities | −$23.8M | $7.1M | −$78.1M | $11.1M | −$30.2M | −$4.4M | $25.0M | −$15.5M | $4.3M | $7.3M | $14.9M | $10.2M |
| Investing activities | ||||||||||||
| Capital expenditures | −$3.9M | −$5.2M | −$5.0M | −$6.0M | −$6.8M | −$4.7M | −$3.8M | −$19.5M | −$12.9M | −$4.1M | −$3.1M | −$4.9M |
| Investments (net) | $54.7M | $71.7M | $16.1M | $19.1M | $53.4M | $27.7M | −$27.5M | $9.0M | $7.3M | −$47.2M | $24.3M | $20.1M |
| Acquisitions & other investing | $0 | −$55.6M | $0 | $6.0M | $6.8M | $4.7M | $3.8M | $19.5M | $12.9M | $4.1M | $3.1M | $4.9M |
| Cash from investing activities | $50.8M | $10.9M | $11.2M | $19.1M | $53.4M | $27.7M | −$27.5M | $9.0M | $7.3M | −$47.2M | $24.3M | $20.1M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | −$23.8M | −$40.1M | −$447,000 | −$357,000 | −$2.5M | −$10.6M | −$242,000 | −$431,000 | −$544,000 | −$1.9M | −$24.0M | −$2.7M |
| Net borrowing (repayment) | −$88,000 | −$564,000 | −$88,000 | −$88,000 | −$88,000 | −$606,000 | −$136,000 | −$136,000 | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$332,000 | −$4.2M | $1,000 | $0 | $0 | $0 | $51,000 | $0 | −$602,000 | −$900,000 | −$2.0M | −$1.8M |
| Cash from financing activities | −$24.2M | −$44.8M | −$534,000 | −$445,000 | −$2.6M | −$11.2M | −$327,000 | −$567,000 | −$1.1M | −$2.8M | −$26.0M | −$4.5M |
| Summary | ||||||||||||
| Net change in cash | $2.9M | −$26.8M | −$67.4M | $29.8M | $20.6M | $12.1M | −$2.9M | −$6.9M | $10.4M | −$42.8M | $13.4M | $25.7M |
| Cash at end of period | $26.3M | $23.4M | $50.3M | $117.8M | $88.0M | $67.4M | $55.3M | $58.2M | $65.1M | $54.7M | $97.5M | $84.1M |
| Free cash flow | −$27.6M | $1.9M | −$83.1M | $5.1M | −$37.0M | −$9.1M | $21.2M | −$35.0M | −$8.7M | $3.2M | $11.8M | $5.3M |
| Free cash flow margin | −32.3% | 2.7% | −99.7% | 6.0% | −45.2% | −12.5% | 27.9% | −48.8% | −12.2% | 5.0% | 16.8% | 6.3% |
| Capex / revenue | 4.5% | 7.3% | 6.0% | 7.2% | 8.3% | 6.4% | 5.0% | 27.2% | 18.2% | 6.3% | 4.4% | 5.8% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
FLGT cash generation
In fiscal 2025 (ended December 31, 2025), Fulgent Genetics generated -$101.6 million of cash from operations (down 582.6%) and spent $22.6 million on capital expenditures, leaving free cash flow of -$124.2 million, −38.5% of revenue. It returned $13.9 million to shareholders through dividends ($0) and net share buybacks ($13.9 million). Cash and equivalents fell by $5.0 million over the year.
Related: FLGT income statement, FLGT balance sheet. See the FLGT stock overview for the latest quote and news.
FLGT cash flow FAQ
What is Fulgent Genetics's free cash flow?
Fulgent Genetics's free cash flow was -$124.2 million in fiscal 2025: -$101.6 million of operating cash flow minus $22.6 million of capital expenditures It was -$19.3 million a year earlier..
How much cash does Fulgent Genetics generate from operations?
Fulgent Genetics generated -$101.6 million of cash from operating activities in fiscal 2025.
How much does Fulgent Genetics spend on capital expenditures?
Fulgent Genetics spent $22.6 million on capital expenditures in fiscal 2025, 7.0% of revenue, compared with $40.3 million the year before.
How much stock does Fulgent Genetics buy back?
Fulgent Genetics spent $13.9 million on net share repurchases in fiscal 2025.